Demographic and Epidemiological Characteristics Associated With Reduced Antimicrobial Susceptibility to Neisseria gonorrhoeae in the United States, Strengthening the US Response to Resistant Gonorrhea, 2018 to 2019.

Autor:	Gieseker KE; From the Colorado Department of Public Health and Environment, Denver, CO., Learner ER; Centers for Disease Control and Prevention, Atlanta, GA., Mauk K; Centers for Disease Control and Prevention, Atlanta, GA., Barbee LA; Department of Medicine, Infectious Diseases, University of Washington, Seattle, WA., McNeil CJ; Wake Forest University School of Medicine/Guilford County Department of Health, Winston-Salem, NC., Hasty GL; Hawaii Department of Health, Honolulu, HI., Black JM; Indiana Department of Health, Indianapolis, IN., Johnson K; New York City Department of Health and Mental Hygiene, New York, NY., Nguyen TQ; San Francisco Department of Public Health, San Francisco, CA., Shrestha D; Milwaukee Health Department, Milwaukee, WI., Pham CD; Centers for Disease Control and Prevention, Atlanta, GA., St Cyr S; Centers for Disease Control and Prevention, Atlanta, GA., Schlanger K; Centers for Disease Control and Prevention, Atlanta, GA., Kirkcaldy RD; Centers for Disease Control and Prevention, Atlanta, GA.
Jazyk:	angličtina
Zdroj:	Sexually transmitted diseases [Sex Transm Dis] 2021 Dec 01; Vol. 48 (12S Suppl 2), pp. S118-S123.
DOI:	10.1097/OLQ.0000000000001541
Abstrakt:	Background: Jurisdictions participating in Strengthening the US Response to Resistant Gonorrhea (SURRG) implemented specimen collection for culture and antimicrobial susceptibility testing from a sample of persons of all genders (at multiple anatomic sites) attending sexually transmitted disease clinics and community clinics. We describe the percentage and characteristics of patients whose isolates demonstrated reduced susceptibility (RS) to azithromycin, ceftriaxone, or cefixime. Methods: We included patients from clinics that participated in SURRG whose isolates underwent antimicrobial susceptibility testing by Etest. We defined RS as azithromycin minimum inhibitory concentrations (MICs) ≥2 μg/mL (AZM-RS), ceftriaxone MICs ≥0.125 μg/mL (CRO-RS), or cefixime MICs ≥0.25 μg/mL (CFX-RS). Patients with repeated infections appeared >1 time in the data. We calculated the frequency and percentage of patients with an isolate demonstrating RS by epidemiological characteristics. Results: During the period 2018-2019, 10,013 patients from 8 jurisdictions provided 10,735 isolates. Among 10,013 patients, 11.0% (n = 1099) had ≥1 isolate with AZM-RS (range by jurisdiction, 2.5%-18.0%). Approximately 11.3% of 8771 of patients visiting sexually transmitted disease clinics and approximately 8.8% of 1242 patients visiting community clinics had an AZM-RS isolate. Nearly 6% of 1013 females had an AZM-RS isolate; among males, the percents of patients with an AZM-RS isolate were 17.7% among 4177 men who have sex only with men and 6.1% among 3581 men who have sex only with women. Few (0.4%) patients had isolates with CFX-RS (n = 40) or CRO-RS (n = 43). Conclusions: Although infections with reduced cephalosporin susceptibility were rare, AZM-RS infections were prevalent in this sample of patients in multiple jurisdictions and across gender and gender of sex partner categories. Competing Interests: Conflict of Interest and Sources of Funding: The authors have no conflicts of interest to disclose. Funding for the Strengthening the US Response to Resistant Gonorrhea activities described in this article was supported by federal Antibiotic Resistance Initiative funding and administered through the US Centers for Disease Control and Prevention's Epidemiology and Laboratory Capacity for the Prevention and Control of Infectious Diseases Cooperative Agreement (CK19-1904). (Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu